AMEUF (Anteris Technologies) ROCE % : -161.50% (As of Mar. 2025)

View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anteris Technologies's annualized ROCE % for the quarter that ended in Mar. 2025 was -161.50%.

Anteris Technologies ROCE % Historical Data

The historical data trend for Anteris Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies ROCE % Chart

Anteris Technologies Annual Data

Trend

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-134.57

-197.68

-257.79

-287.11

-176.85

Anteris Technologies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-297.20	-1,312.22	-	-	-161.50

Anteris Technologies ROCE % Calculation

Anteris Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-75.92	/	( ( (31.136 - 9.419)	+	(80.699 - 16.56) )	/ 2 )
	=	-75.92	/	( (21.717	+	64.139)	/ 2 )
	=	-75.92	/	42.928
	=	-176.85 %

Anteris Technologies's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-87.62	/	( ( (80.699 - 16.56)	+	(58.792 - 14.425) )	/ 2 )
	=	-87.62	/	( ( 64.139	+	44.367 )	/ 2 )
	=	-87.62	/	54.253
	=	-161.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

Anteris Technologies (OTCPK:AMEUF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anteris Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AVR:Australia

Address

9 Sherwood Road, Level 3, Suite 302, Toowong, QLD, AUS, 4066

Website

https://www.anteristech.com

Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.